Dollar Industries Q3 FY26 Results: Standalone PAT up 25% in 9M

Profit growth above 25%Related-party transactionsResults View source PDF Explain this filing

DOLLAR · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-7.7%Reaction day

₹339.00

prior close

₹320.00

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.5%-7.2% vs market

Garments & Apparels peers, median of 35sector-0.3%-7.4% vs sector

On the reaction day the stock moved 7.2 pts less than Nifty Microcap 250 and 7.4 pts less than its Garments & Apparels peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.3

10m

+1.2

15m

+0.7

30m

+0.2

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-7.7-0.5-7.2-0.3-7.4

Next day

-8.3-2.0-6.4-1.5-6.8

-9.6-2.7-6.9-1.9-7.7

-6.8-1.7-5.1-1.6-5.1

-7.8-1.4-6.4-2.9-4.9

-10.6-2.8-7.8-4.4-6.2

-11.6-2.8-8.8-4.3-7.4

15d

-20.3-8.4-11.9-12.6-7.7

-24.5-9.1-15.4-13.6-10.9

-21.5-4.0-17.5-9.7-11.8

-17.7+2.6-20.3-12.2-5.5

UpDownMarket · Nifty Microcap 250Sector · Garments & Apparels peers, median of 35Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Dollar Industries Q3 FY26 (Dec 2025) standalone revenue rose 2.8% YoY to Rs 388.2 cr. Standalone PAT fell 27.8% to Rs 19.2 cr. For 9M FY26, standalone PAT grew 25% to Rs 74.3 cr on Rs 1,242 cr revenue. Consolidated 9M PAT was Rs 74.1 cr. Board approved a composite scheme to consolidate group entities and prune related party transactions; awaits NSE and BSE approval.

Likely market impact

Mixed quarter; weak Q3 PAT but strong 9M growth. Scheme consolidation may simplify structure. Watch for NSE/BSE and NCLT approvals.